Travere Therapeutics market cap TVTX
Share price times shares outstanding: what the whole company sells for, since 2013.
- Today, Nov 2, 2026
- $4.6B
- Highest close in our data
- $6.2B
- Sep 2026
Travere Therapeutics is worth $4.6B at the close on Nov 2, 2026, at $49.26 a share.
That is up 60% over the last year and up 152% over five years.
Its highest close in our data was $6.2B in Sep 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $4.6B | $2.5B | $6.2B | +31% |
| 2025 | $3.5B | $1.3B | $3.5B | +163% |
| 2024 | $1.3B | $400.3M | $1.5B | +100% |
| 2023 | $675.6M | $419.3M | $1.5B | −50% |
| 2022 | $1.3B | $1.2B | $1.9B | −29% |
| 2021 | $1.9B | $799.9M | $1.9B | +37% |
| 2020 | $1.4B | $476.9M | $1.4B | +125% |
| 2019 | $617.3M | $480.2M | $970.1M | −33% |
| 2018 | $919M | $834.5M | $1.3B | +11% |
| 2017 | $828.2M | $630.2M | $958.1M | +16% |
| 2016 | $714.3M | $457.1M | $890.7M | +2% |
| 2015 | $697.3M | $338.3M | $1.3B | +101% |
| 2014 | $346.6M | $154.4M | $461.7M | +173% |
| 2013 | $127M | $57.3M | $159.9M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Travere Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| TVTXTravere Therapeutics | $4.6B |
| INDVIndivior Pharmaceuticals | $4.3B |
| ARQTArcutis Biotherapeutics | $3.9B |
| LQDALiquidia | $3.7B |
| OGNOrganon | $3.6B |
| LGNDLigand Pharmaceuticals | $6.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| ALKSAlkermes plc. | $7.5B |
| NRIXNurix Therapeutics | $2.8B |
| CORTCorcept Therapeutics | $8.7B |
| Peer median | $5.2B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Travere Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.